HC Wainwright restated their buy rating on shares of Fibrocell Science Inc (NASDAQ:FCSC) in a research report released on Thursday morning. HC Wainwright currently has a $7.60 price objective on the stock.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Fibrocell Science from a sell rating to a hold rating in a research note on Friday, September 22nd. Canaccord Genuity restated a buy rating and issued a $7.00 target price (up previously from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. Finally, ValuEngine downgraded shares of Fibrocell Science from a sell rating to a strong sell rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $5.21.

Fibrocell Science (NASDAQ:FCSC) traded down 4.25% during mid-day trading on Thursday, hitting $2.93. 134,759 shares of the company were exchanged. The company’s market cap is $43.12 million. The stock’s 50 day moving average is $3.00 and its 200-day moving average is $2.80. Fibrocell Science has a 12-month low of $1.57 and a 12-month high of $4.64.

Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.31). Equities research analysts predict that Fibrocell Science will post ($2.17) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/06/fibrocell-sciences-fcsc-buy-rating-reaffirmed-at-hc-wainwright.html.

A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC lifted its holdings in Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,259 shares of the company’s stock after buying an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.33% of Fibrocell Science worth $194,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 54.70% of the company’s stock.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Stock Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related stocks with our FREE daily email newsletter.